Monoclonal antibody successes in the clinic

By J. Reichert, C. J. Rosensweig, Laura B Faden, Matthew C. Dewitz. Nature Biotechnology, 2005

757 citations recorded by the source corpus.

Subfields: Immunology, Oncology, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/fa1a1df3e49c37b1a539c6938221a50de4d36ec4

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. D. Baty
2. M. H. V. Van Regenmortel
3. Etienne Weiss
4. P. Carter
5. P. Chames
6. A. Takaoka
7. Shizuo Akira

In Oncology

1. K. Imai
2. A. Takaoka
3. D. Baty
4. Peter L. Choyke
5. Hisataka Kobayashi
6. M. H. V. Van Regenmortel
7. Etienne Weiss
8. Paul Polakis

In Radiology, Nuclear Medicine and Imaging

1. K. Imai
2. A. Takaoka
3. D. Baty
4. M. H. V. Van Regenmortel
5. Etienne Weiss
6. Paul Polakis
7. S. Bhakta
8. S. Panowski

Citations in the corpus

• Development trends for human monoclonal antibody therapeutics (2010, background): “jpg"/> Human monoclonal antibodies (mAbs) are the fastest-growing category of mAb therapeutics entering clinical stud”
• Cancer Cell-Selective In Vivo Near Infrared Photoimmunotherapy Targeting Specific Membrane Molecules (2011, background): “Among the existing targeted therapies, therapy with mAbs has the longest history, and, to date, over 25 therapeutic mAbs have been approved by the US Food and Drug Administratio”
• The safety and side effects of monoclonal antibodies (2010, background): “This has led to mAbs having marked successes in the clini”
• Therapeutic antibodies: successes, limitations and hopes for the future (2009, positive): “…conserved through evolution, it was possible to create chimeras by fusing murine variable domains, responsible for the binding activity, with human constant domains (Neuberger et al., 1985) leading to the development of a new generation of therapeutic candidates (Reichert et al., 2005) (Figure 1).”
• Comparing antibody and small-molecule therapies for cancer (2006, background): “Furthermore, chimeric and humanized mAbs, which have been the predominant mAbs entering clinical studies, have higher approval success rates (18% and 24%, respectively”
• Site-specific antibody drug conjugates for cancer therapy (2013, background): “Antibodies can also impart therapeutic benefit by binding and inhibiting the function of target antigens, as in the case of trastuzumab (Herceptin), bevacizumab (Avastin), and cetuximab (Erbitux).(2) However, antibodies against tumor-specific antigens often lack therapeutic activity.”
• Potent antibody therapeutics by design (2006, background): “At least 150 additional antibodies are in clinical developmen”